Logo image of VSTM

VERASTEM INC (VSTM) Stock Fundamental Analysis

USA - NASDAQ:VSTM - US92337C2035 - Common Stock

9.11 USD
+0.06 (+0.66%)
Last: 9/22/2025, 3:29:58 PM
Fundamental Rating

1

VSTM gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 538 industry peers in the Biotechnology industry. VSTM may be in some trouble as it scores bad on both profitability and health. VSTM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VSTM has reported negative net income.
VSTM had a negative operating cash flow in the past year.
VSTM had negative earnings in each of the past 5 years.
In the past 5 years VSTM always reported negative operating cash flow.
VSTM Yearly Net Income VS EBIT VS OCF VS FCFVSTM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -66.56%, VSTM is doing worse than 60.97% of the companies in the same industry.
The Return On Equity of VSTM (-362.32%) is worse than 74.16% of its industry peers.
Industry RankSector Rank
ROA -66.56%
ROE -362.32%
ROIC N/A
ROA(3y)-88.21%
ROA(5y)-74.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VSTM Yearly ROA, ROE, ROICVSTM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

VSTM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VSTM Yearly Profit, Operating, Gross MarginsVSTM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

2

2. Health

2.1 Basic Checks

VSTM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VSTM has been increased compared to 1 year ago.
The number of shares outstanding for VSTM has been increased compared to 5 years ago.
VSTM has a worse debt/assets ratio than last year.
VSTM Yearly Shares OutstandingVSTM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
VSTM Yearly Total Debt VS Total AssetsVSTM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -6.41, we must say that VSTM is in the distress zone and has some risk of bankruptcy.
VSTM has a worse Altman-Z score (-6.41) than 65.24% of its industry peers.
VSTM has a Debt/Equity ratio of 2.25. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of VSTM (2.25) is worse than 80.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.25
Debt/FCF N/A
Altman-Z -6.41
ROIC/WACCN/A
WACC9.98%
VSTM Yearly LT Debt VS Equity VS FCFVSTM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

VSTM has a Current Ratio of 3.46. This indicates that VSTM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.46, VSTM is in line with its industry, outperforming 40.71% of the companies in the same industry.
VSTM has a Quick Ratio of 3.44. This indicates that VSTM is financially healthy and has no problem in meeting its short term obligations.
VSTM has a Quick ratio (3.44) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.46
Quick Ratio 3.44
VSTM Yearly Current Assets VS Current LiabilitesVSTM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 6.89% over the past year.
The Revenue for VSTM have been decreasing by -10.55% on average. This is quite bad
EPS 1Y (TTM)6.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.81%
Revenue 1Y (TTM)N/A
Revenue growth 3Y69.6%
Revenue growth 5Y-10.55%
Sales Q2Q%-78.63%

3.2 Future

VSTM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.93% yearly.
VSTM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 124.75% yearly.
EPS Next Y22.19%
EPS Next 2Y18.22%
EPS Next 3Y17.01%
EPS Next 5Y22.93%
Revenue Next Year106.49%
Revenue Next 2Y220.88%
Revenue Next 3Y185.82%
Revenue Next 5Y124.76%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VSTM Yearly Revenue VS EstimatesVSTM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
VSTM Yearly EPS VS EstimatesVSTM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VSTM. In the last year negative earnings were reported.
Also next year VSTM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VSTM Price Earnings VS Forward Price EarningsVSTM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VSTM Per share dataVSTM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as VSTM's earnings are expected to grow with 17.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.22%
EPS Next 3Y17.01%

More info and screens

0

5. Dividend

5.1 Amount

VSTM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERASTEM INC

NASDAQ:VSTM (9/22/2025, 3:29:58 PM)

9.11

+0.06 (+0.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-04 2025-11-04
Inst Owners84.73%
Inst Owner Change24.8%
Ins Owners0.62%
Ins Owner Change-1.19%
Market Cap560.72M
Analysts85.33
Price Target15.81 (73.55%)
Short Float %27.4%
Short Ratio6.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)19.76%
Min EPS beat(2)-8.89%
Max EPS beat(2)48.42%
EPS beat(4)2
Avg EPS beat(4)-0.42%
Min EPS beat(4)-61.48%
Max EPS beat(4)48.42%
EPS beat(8)4
Avg EPS beat(8)-0.76%
EPS beat(12)7
Avg EPS beat(12)1.59%
EPS beat(16)8
Avg EPS beat(16)-2.55%
Revenue beat(2)1
Avg Revenue beat(2)-6.6%
Min Revenue beat(2)-100%
Max Revenue beat(2)86.8%
Revenue beat(4)1
Avg Revenue beat(4)-53.3%
Min Revenue beat(4)-100%
Max Revenue beat(4)86.8%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.64%
PT rev (3m)-1.59%
EPS NQ rev (1m)5.73%
EPS NQ rev (3m)-5.2%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)2.48%
Revenue NQ rev (3m)-2.86%
Revenue NY rev (1m)1.31%
Revenue NY rev (3m)-17.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 56.07
P/FCF N/A
P/OCF N/A
P/B 15.55
P/tB 27.46
EV/EBITDA N/A
EPS(TTM)-3.11
EYN/A
EPS(NY)-2.11
Fwd EYN/A
FCF(TTM)-1.95
FCFYN/A
OCF(TTM)-1.95
OCFYN/A
SpS0.16
BVpS0.59
TBVpS0.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -66.56%
ROE -362.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.21%
ROA(5y)-74.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 2.25
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.46
Quick Ratio 3.44
Altman-Z -6.41
F-Score5
WACC9.98%
ROIC/WACCN/A
Cap/Depr(3y)35.9%
Cap/Depr(5y)41.04%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.81%
EPS Next Y22.19%
EPS Next 2Y18.22%
EPS Next 3Y17.01%
EPS Next 5Y22.93%
Revenue 1Y (TTM)N/A
Revenue growth 3Y69.6%
Revenue growth 5Y-10.55%
Sales Q2Q%-78.63%
Revenue Next Year106.49%
Revenue Next 2Y220.88%
Revenue Next 3Y185.82%
Revenue Next 5Y124.76%
EBIT growth 1Y-24.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5Y36.99%
FCF growth 1Y-67.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-67.27%
OCF growth 3YN/A
OCF growth 5YN/A